Giulia Mallucci1, P Annovazzi2, S Miante3, V Torri-Clerici4, M Matta5, S La Gioia6, R Cavarretta7, V Mantero8, G Costantini9, V D'Ambrosio10, M Zaffaroni2, A Ghezzi2, P Perini3, S Rossi4, A Bertolotto5, M R Rottoli6, M Rovaris7, R Balgera8, P Cavalla9, C Montomoli11, R Bergamaschi10. 1. Inter-department Multiple Sclerosis Research Centre, IRCCS Mondino Mondino, Pavia, Italy. giulia.mallucci@mondino.it. 2. Multiple Sclerosis Study Centre, ASST Valle Olona, Gallarate, VA, Italy. 3. Department of Neurosciences, The Multiple Sclerosis Centre, University Hospital of Padova, Padua, Italy. 4. Department of Neuroimmunology and Neuromuscular Diseases, Neurological Institute C, Besta IRCCS Foundation, Milan, Italy. 5. Regional Multiple Sclerosis Centre, San Luigi Gonzaga Hospital, Orbassano, TO, Italy. 6. SS Malattie Autoimmuni USC Neurologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. 7. Multiple Sclerosis Center, IRRCS Santa Maria Nascente, Fondazione Don Carlo Gnocchi, Milan, Italy. 8. Neurological Department, A. Manzoni Hospital, Lecco, Italy. 9. Department of Neuroscience, University of Torino, Turin, Italy. 10. Inter-department Multiple Sclerosis Research Centre, IRCCS Mondino Mondino, Pavia, Italy. 11. Unit of Biostatistics and Clinical Epidemiology, Department of Public Health, University of Pavia, Pavia, Italy.
Abstract
BACKGROUND: Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. OBJECTIVES: To track and evaluate post-market DMF profile in real-world setting. MATERIALS AND METHODS: Patients receiving DMF referred to Italian MS centres were enrolled and prospectively followed, collecting demographic clinical and radiological data. RESULTS: Among the 735 included patients, 45.4% were naïve to disease-modifying therapies, 17.8% switched to DMF because of tolerance, 27.4% switched to DMF because of lack of efficacy, and 9.4% switched to DMF because of safety concerns. Median DMF exposure was 17 months (0-33). DMF reduced the annual relapse rate (ARR) by 63.2%. At 12 and 24 months, 85 and 76% of patients were relapse-free. NEDA-3 status after 12 months of DMF treatment was maintained by 47.5% of patients. 89 and 70% of patients at 12 and 24 months regularly continued DMF. Most frequent adverse events (AEs) were flushing (37.2%) and gastro-enteric AEs (31.1%). CONCLUSION: Our post-market study corroborated that DMF is a safe and effective drug. Additionally, the study suggested that naïve patients strongly benefit from DMF and that DMF improved ARR also in patients who were horizontally switched from injectable therapies due to tolerability and efficacy issues.
BACKGROUND:Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. OBJECTIVES: To track and evaluate post-market DMF profile in real-world setting. MATERIALS AND METHODS:Patients receiving DMF referred to Italian MS centres were enrolled and prospectively followed, collecting demographic clinical and radiological data. RESULTS: Among the 735 included patients, 45.4% were naïve to disease-modifying therapies, 17.8% switched to DMF because of tolerance, 27.4% switched to DMF because of lack of efficacy, and 9.4% switched to DMF because of safety concerns. Median DMF exposure was 17 months (0-33). DMF reduced the annual relapse rate (ARR) by 63.2%. At 12 and 24 months, 85 and 76% of patients were relapse-free. NEDA-3 status after 12 months of DMF treatment was maintained by 47.5% of patients. 89 and 70% of patients at 12 and 24 months regularly continued DMF. Most frequent adverse events (AEs) were flushing (37.2%) and gastro-enteric AEs (31.1%). CONCLUSION: Our post-market study corroborated that DMF is a safe and effective drug. Additionally, the study suggested that naïve patients strongly benefit from DMF and that DMF improved ARR also in patients who were horizontally switched from injectable therapies due to tolerability and efficacy issues.
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: Edward J Fox; Alberto Vasquez; William Grainger; Tina S Ma; Christian von Hehn; John Walsh; Jie Li; Javier Zambrano Journal: Int J MS Care Date: 2016 Jan-Feb
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: E Havrdova; G Giovannoni; R Gold; R J Fox; L Kappos; J Theodore Phillips; M Okwuokenye; J L Marantz Journal: Eur J Neurol Date: 2017-03-22 Impact factor: 6.089
Authors: Ralf Gold; Douglas L Arnold; Amit Bar-Or; Michael Hutchinson; Ludwig Kappos; Eva Havrdova; David G MacManus; Tarek A Yousry; Carlo Pozzilli; Krysztof Selmaj; Marianne T Sweetser; Ray Zhang; Minhua Yang; James Potts; Mark Novas; David H Miller; Nuwan C Kurukulasuriya; Robert J Fox; Theodore J Phillips Journal: Mult Scler Date: 2016-07-11 Impact factor: 6.312
Authors: E D'Amico; A Zanghì; M Sciandra; G Borriello; G Callari; A Gallo; G Salemi; S Cottone; M Buccafusca; P Valentino; R B Bossio; L M E Grimaldi; C Pozzilli; G Tedeschi; M Zappia; F Patti Journal: J Neurol Date: 2018-12-04 Impact factor: 4.849
Authors: Belen Pilo de la Fuente; Julia Sabín; Victoria Galán; Israel Thuissard; Susana Sainz de la Maza; Lucienne Costa-Frossard; Mayra Gómez-Moreno; Judit Díaz-Díaz; Celia Oreja-Guevara; Alberto Lozano-Ros; José M García-Domínguez; Laura Borrego; Lucía Ayuso; Andy Castro; Pedro Sánchez; Virginia Meca-Lallana; Carmen Muñoz; Ignacio Casanova; Carlos López de Silanes; Hugo Martín; Elena Rodríguez-García; Cristina Andreu-Vázquez; Rosario Blasco; Juan A García-Merino; Yolanda Aladro Journal: CNS Drugs Date: 2020-11-23 Impact factor: 5.749
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Ana Rodríguez-Regal; Laura Ramos-Rúa; Luis Anibarro-García; Ana María Lopez Real; María Del Campo Amigo-Jorrín Journal: Patient Prefer Adherence Date: 2021-01-29 Impact factor: 2.711
Authors: Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits Journal: Neurol Int Date: 2021-05-19
Authors: Trudy L Campbell; Béatrice Jenny Lefaux; Lori Lee Mayer; Marie Namey; Gisela Riemer; Miguel A Robles-Sanchez; Sarah White; Michael Edwards; Charles Minor Journal: J Neurosci Nurs Date: 2020-04 Impact factor: 1.627